Corbus Pharma Aligns With FDA On Registration Path For CRB-701 In HNSCC And Cervical Cancer

Corbus Pharmaceuticals said it broadly aligned with the FDA on the registration path for CRB-701, a stable Nectin-4–targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical cancer. The regulatory alignment reduces development/regulatory risk and could accelerate a registration pathway, likely positive for CRBP shares and potentially moving the stock by low single-digit percentages as investors reprice approval probability.

Analysis

Corbus Pharmaceuticals said it broadly aligned with the FDA on the registration path for CRB-701, a stable Nectin-4–targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical cancer. The regulatory alignment reduces development/regulatory risk and could accelerate a registration pathway, likely positive for CRBP shares and potentially moving the stock by low single-digit percentages as investors reprice approval probability.